Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | CI Cigna | ABT Abbott Laboratories |
|---|---|---|
| Price | $280.45 -2.9% | $102.36 +0.3% |
| StockIQ Score | 59C Moderate Risk: High | 51C- Moderate Risk: Medium |
| Technical | 52C- | 23F |
| Fundamental | 50C- | 72B |
| Growth | 71B | 45D+ |
| Fair Value | 55C | 38F |
| News | 100A+ | 92A+ |
| Quality | 47D+ | 63C+ |
| Risk | 40D | 54C- |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Cigna outperforms Abbott in growth (71 vs. 45) and valuation (55 vs. 38), showing stronger potential for expansion and better pricing relative to earnings. However, Abbott leads in fundamentals (72 vs. 50), indicating a more stable financial foundation. Both share a moderate investor rating, but their strengths differ—growth for Cigna, stability for Abbott.